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4G/5G, C>GBackground: Many genetic factors, including polymorphisms in the genes regulating blood coagulation
and fibrinolysis have been proposed as risk factors for coronary artery disease (CAD). PAI-1 is the chief
inhibitor of tissue plasminogen activator and urokinase plasminogen activator. PAI-1 has a crucial role
in regulation of fibrinolysis.
Aim of the study: Is to investigate the association between Plasminogen activator inhibitor-1 (PAI-1)
4G/5G, PAI-1C/G polymorphisms and CAD. In addition, studying the relation of these polymorphisms
to the level of active PAI-1 in Egyptian patients presenting to a single tertiary center in Cairo.
Subjects and methods: One hundred and forty-four patients were included in this study: 42 STEMI (ST ele-
vation myocardial infarction) patients, 63 stable angina patients, and 39 as a control group. Detection of
PAI-1 4G/5G and C > G polymorphisms was done using allele specific polymerase chain reaction and
restriction fragment length polymorphism (RFLP) respectively. Plasma plasminogen activator inhibitor-
1 activity was detected using enzyme linked immunosorbent assay (ELISA).
Results: In the studied CAD patients, PAI-14G/5G polymorphism showed 31.7%, and 68.3% for 5G/5G, and
(4G/5G + 4G/4G) respectively; however for the control group, 5G/5G, and (4G/5G + 4G/4G) were detected
in 21.6%, and 78.4% respectively (p value 0.59). The genotypic frequencies for PAI-1C/G in CAD patients
accounted for 27% (CC), 73% (CG + GG); while in the control group these frequencies were 35.3%, and
64.7% respectively (p value 1.43).
Conclusion: No significant association between PAI-1 4G/5G and C > G polymorphisms and the risk of
coronary artery disease or the activity level of PAI-1 among the studied Egyptian population sample.
However, STEMI patients showed significant presence of combined mutant allele of both genes more
frequently.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery disease (CAD) is one of the leading causes of
morbidity and mortality in the modern world. Despite the
improvement in diagnosis and treatment options, its prevalence
is still high [1]. Nuclear cardiac imaging has been extensively used
as a diagnostic and prognostic tool for CAD. Negative stress
myocardial perfusion study on maximal exercise correlated with
normal coronary angiographies. Furthermore, it carried excellentprognosis with a sensitivity approaching 98%. Patients showing
positive scans on exercise were previously categorized as Stable
Angina patients in the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation (COURAGE) trial [2]. A num-
ber of risk factors have been linked to CAD, among these factors:
hyperlipidemia, hypertension, diabetes, smoking, family history
and obesity [3,4]. These classical predisposing factors could explain
about half of the cases of coronary artery disease. Moreover, stud-
ies on twins and family history had explored a possible role of
genetic alterations as contributors to CAD [5–7].
Genes involved in blood coagulation and fibrinolysis processes,
lipid metabolism and blood pressure regulation have been impli-
cated as genetic risk factors for CAD. [8].
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important factor in determining the severity of CAD. CAD may
range from unstable angina, associated with the non-occlusive
thrombus to more severe form of disease; ST-elevated myocardial
infarction (STEMI) accompanying the occlusive thrombus forma-
tion [9].
Myocardial infarction (MI) may result as a consequence of
atherosclerotic plaque rupture, which stimulates blood coagula-
tion resulting in occlusive thrombus and cardiac tissue necrosis
[9,10]
Plasminogen activator inhibitor (PAI-1) has a pivotal role in reg-
ulation of fibrinolysis. The PAI-1 encoding gene is located on the
short arm of chromosome 7 and consists of 9 exons [11]. PAI-1 is
synthesized in the endothelial cells, liver, spleen and adipose tis-
sue. It is stored and released from platelets on its activation
[12,13]. It is the chief inhibitor of tissue plasminogen activator
and urokinase plasminogen activator. Thus, PAI-1 stops the conver-
sion of plasminogen into plasmin, the latter being in control of
degradation of fibrin clots [13,14]. Increased expression of PAI-1
may hinder normal fibrin clearance and predispose to throm-
bophilia [15].Multiple single nucleotide polymorphisms in the
PAI-1 gene have been investigated. Among these polymorphisms:
4G/5G insertion/deletion polymorphism at 675 bp of the gene
promoter, in addition to C > G polymorphism at the 30untranslated
region (UTR) [16]. PAI-1 4G/5G gene polymorphism and the risk of
CAD was thoroughly studied with conflicting data; some studies
approving its role in the increased risk of CAD [17,18] while others
did not [19,20].
This preliminary study aimed at evaluating the possible role of
PAI-1 4G/5G and PAI-1C > G polymorphisms in Egyptian patients
with CAD compared to a group of non-ischemic patients.Table 1
Primer sequences for PAI-1 polymorphisms.
Genetic
polymorphism
Primer sequence Thermal cycler
conditions







94 C for 3 min 30
cycles of:
Denaturation 94 C for
30 s, Annealing 60 C
for 30 s, Extension 72
C for 30 s,









94 C for 3 min,
32 cycles* of:
Denaturation 94 C for
35 s, Annealing 65 C
for 35 s, Extension 72
C for 70 s,




















* PCR thermal conditions were the same for the 5G and 4G allele reactions, except
for the final 22 cycles in 5G allele reactions, in which the annealing temperature
was 58 C.2. Subjects and methods
This was a prospective, double blind, case control, pilot, single
tertiary center study. The study was conducted on patients admit-
ted or subjected to myocardial perfusion imaging in the Critical
Care Center, Faculty of medicine, Cairo University. The ethical com-
mittee of the Faculty of Medicine, Cairo University, approved the
study. Informed written consents were taken from the patients
for their participation in the study. The work has been carried
out in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments in human
patients. The blood samples were collected, coded and stored in
the Critical Care Center and then processed in the Clinical Pathol-
ogy Department blindly. The laboratory test results were sent
directly to the statistician, similarly the clinical and myocardial
perfusion data were sent directly to the statistician.
2.1. Subjects
2.1.1. Inclusion criteria
All patients with ST segment elevation myocardial infarction
(STEMI) admitted to the Critical Care Center and subjected to pri-
mary percutaneous coronary intervention (PCI) were included as
STEMI patients [21]. Patients scheduled for stress-rest technetium
99 m sestaMIBI (methoxy Isobutyryl Isonitrite) myocardial perfu-
sion studies with abnormal scans were included as stable angina
patients [22]. While patients with negative scan results for ische-
mia upon maximal exercise testing were considered as controls.
2.1.2. Exclusion criteria
Patients above 70 years, patients with cardiogenic shock, in
addition to patients who refused to be enrolled in the study were
excluded from the study.2.2. Methods
2.2.1. History taking and laboratory investigations
History was taken from patients for possible CAD risk factors.
Withdrawal of 2 ml venous blood sample on trisodium citrate
tubes was done for determination of plasma PAI-1 activity accord-
ing to the manufacturer’s instructions using enzyme linked
immunosorbent assay (ELISA) kit (Zymutest PAI-1 activity,
HYPHEN BioMed, France). In addition, withdrawal of 2 ml venous
blood sample under complete aseptic conditions in vacuum tubes
containing ethylene-diamine-tetra-acetic acid (EDTA) to be stored
at 20 C for later DNA extraction. Subsequent detection of PAI-1
4G/5G and C > G polymorphisms using allele specific polymerase
chain reaction and restriction fragment length polymorphism
(RFLP) respectively was done.2.2.2. DNA extraction and genotyping
Genomic DNA was extracted using the QIAamp DNA blood mini
kit (Qiagen, Germany) according to the manufacturer’s instruc-
tions. Amplification of DNA for target polymorphisms detection
was performed in a 25 ll volume reaction. The reaction consisted
of: 7 ll extracted DNA, 1 ll of the corresponding forward primer
and 1 ll of the corresponding reverse primer (20 pmol), 12.5 ll
master mix (Dreamtaq Green PCR master mix, Thermo Scientific,
USA) and 3.5 ll nuclease free water. Amplification was performed
in an automated thermal cycler (Applied Biosystems, USA). The pri-
mer sequences and amplification thermal PCR conditions are listed
in Table 1.
For the PAI-1 4G/5G polymorphism: two reactions were per-
formed; each reaction contains a sense control primer, a common
antisense primer and an allele specific primer (4G or 5G). An
amplified 257 bp control band formed by sense and antisense pri-
mers was present in both reactions. In addition, a 136 bp band was
observed for each 4G and 5G reactions if their alleles were present.
4G/4G homozygotes yielded 257-bp and 136-bp bands for the 4G
allele-specific reaction and a 257-bp band for the 5G allele-
specific reaction. 4G/5G heterozygotes showed 257- and 136-bp
bands for both reactions. Whereas 5G/5G homozygotes showed a
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and 136-bp bands for the 5G allele-specific reactions [23]. As for
the PAI C > G polymorphism: amplification yielded a 755 bp band.
Amplified DNA was digested with 5 ll of HindIII restriction
enzyme (New England Biolabs, USA) at 37 C for 1 h. A 567 and
188 bp fragments represented the C/C wild-type genotype for the
PAI-1C > G polymorphism, whereas 755 bp band corresponded to
the G/G polymorphic genotype. All fragments were analyzed by
electrophoresis on 2% agarose gel and stained with ethidium bro-
mide [24].2.2.3. STEMI patients
Patients with STEMI were subjected to clinical examination, 12
lead electrocardiogram (ECG) and Primary PCI by experienced
operators within 90 min of admission. In addition, withdrawal of
blood samples on admission for routine baseline laboratory inves-
tigations, before administration of any anticoagulant or antiplate-
let therapy. Creatine kinase (CK), and CK-MB every 6 h for 24 h
to detect enzyme peak level, were assayed as per center protocol.2.2.4. Myocardial perfusion imaging
Patients scheduled for technetium (Tc99m) sestaMIBI myocar-
dial perfusion imaging were subjected to ischemia provocation
stress testing. This was done using Treadmill exercise stress test
according to Bruce protocol to reach 100% of the target predicted
heart rate or termination of exercise upon development of chest
pain, ECG changes or serious arrhythmias [25]. Patients with exer-
cise terminated due to physical fatigue or who didn’t reach the tar-
get heart rate were excluded. A dose of 15–20 mCi of technetium
sestaMIBI was injected during the peak of exercise to acquire the
first set of images (stress images). Another similar dose of tech-
netium sestaMIBI was injected on a separate day at rest to acquire
the rest images. Single photon emission computed tomography
(SPECT) Image acquisition was done using a double head Siemens
Symbia gamma camera (USA). Frames were acquired 30 s each
over 120 arc to get 2 studies (stress-rest) demonstrated as a com-
parison display showing the classical short axis, vertical long axis
and horizontal long axis slices. The images were processed using
Cedars Sinai software, (2007, USA). Myocardial perfusion scans
were interpreted and revised by 2 experienced investigators.2.2.5. Statistical analysis
Data were analyzed using IBM SPSS advanced statistics version
20 (SPSS Inc., Chicago, IL). Numerical data were expressed as med-
ian and range or mean and standard deviation when appropriate.
Qualitative data were expressed as frequency and percentage.
Chi-square test (Fisher’s exact test) was used to examine the rela-
tion between qualitative variables. For quantitative data, compar-
ison between two groups was done using either Student t-test or
Mann-Whitney test as appropriate. Comparison between 3 groups
was done using Kruskal-Wallis test (non-parametric ANOVA) then
multiple comparisons was done based on Kruskal-Wallis test. Odds
ratio (OR) with 95% confidence interval (CI) was used for risk esti-
mation. Spearman-rho method was used to test correlation
between numerical variables. A p-value < 0.05 was considered
significant.3. Results
3.1. Patients’ characteristics
One hundred and forty-four patients were included in the
study: 42 STEMI patients, 63 stable angina patients, and 39 as a
control group.Mean age of the studied subjects was 61 ± 10.3 years. Compared
to controls, all risk factors for CAD (except dyslipidemia) were sig-
nificantly more prevalent in the STEMI and Stable Angina patients
(Table 2). The CK and CK-MB on admission and peak levels are
shown in Fig. 1. The mean number of perfusion defects in Stable
Angina patients was 1.6 ± 0.9.3.2. PAI polymorphism
PAI-1 4G/5G gene polymorphism genotypes and allele frequen-
cies did not differ significantly between the three studied groups
(Tables 3 and 4). The 4G4G mutant genotype was detected in only
2 patients with stable angina, so we considered patients with
4G/4G or 4G/5G as one group.
PAI-1C > G polymorphism genotypes and allele frequencies did
not differ significantly between the three studied groups (Tables 3,
and 4). The GG mutant genotype was detected in 10 STEMI
patients, 4 patients with stable angina, and in only 2 of the control
group so we considered patients with GG and CG genotypes as one
group.
In addition, CK and CK-MB and their peak levels did not differ
significantly between mutant and non-mutant genotypes in both
polymorphisms (p value > 0.05).
Most of the heterozygous STEMI patients (89.2%) for 4G5G poly-
morphism were found to have simultaneously either mutant GG
genotype (35.7%) or one mutant G allele (53.6%) for PAI C > G poly-
morphism (p value 0.016).3.3. PAI-1. Activity
The expected normal level for PAI-1 activity is < 5 ng/ml accord-
ing to manufacturer’s instruction as most of the PAI-1 is in the
latent or in the inactive form. Comparison of the level of PAI-1
activity between the 3 studied groups did not yield any significant
difference (Table 5). In addition, PAI activity did not differ signifi-
cantly between different genotypes of PAI polymorphisms among
the different groups (Table 6). No correlations between PAI activity
and different parameters including age, lipid profile, CK and CK-MB
levels, fibrinogen or number of defects among STEMI patients were
detected (p value > 0.05).3.4. CAD risk factors
Diabetes, smoking and hypertension were more prevalent in
CAD patients compared to the controls while the prevalence of
dyslipidemia, family history, genotypic and allelleic frequencies
of the studied PAI 4G/5G, PAI C/G were similar among CAD and
controls.
(Table 4).4. Discussion
Discovering new CAD risk factors at the level of genetic regula-
tion of the coagulation and fibrinolysis cascades was subjected to
intense research investigations. These research studies aimed at a
better prediction and consequently prevention of this critical con-
dition. Many polymorphisms have been implicated in the patho-
physiology of CAD [26]. Among these are: polymorphisms of PAI-
1 at different sites of the gene, which are important in determining
PAI-1 activity thus controlling the balance between coagulation
and fibrinolysis [27].
PAI-1 gene polymorphisms could change its generation level.
Moreover it has been linked to worsening of some thrombotic dis-
eases; as coronary heart disease, atherosclerosis and stroke [28,29].
Table 2
Comparison of demographic data and risk factors among STEMI, stable angina and the control groups.
STEMI* N = 42 Stable angina N = 63 Control N = 39 P value




























































* STEMI; ST elevation myocardial infarction.
** P value < 0.05 is significant.
*** Family history.
**** Coronary artery disease.
Fig. 1. CK and CK-MB levels among STEMI patients.
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4G/5G, PAI-1C/G polymorphisms and the risk of coronary artery
disease and their relation to PAI-1 activity.
The clinical practice guidelines (CPG) published by the Euro-
pean Society of Cardiology (ESC) emphasized the high prevalence
of STEMI in women and elderly and commented on the diagnostic
difficulties encountered in these populations [30]. The present
study showed a significantly higher age among the STEMI patients
compared to the other 2 groups. Acute coronary syndrome (ACS)
exists three to four times more common in men than in womenTable 3
Genotypic frequencies of PAI-1 4G/5G, and PAI-1C > G polymorphisms in the studied grou
STEMI* N (%) Stable angin
PAI 4G/5G polymorphism
5G/5G 11(26.8%) 22(34.9%)
4G/4G + 4G/5G 30 (73.2%) 41(65.1%)
PAI C > G polymorphism
CC 7(20.6%) 13(32.5%)
CG + GG 27(79.4%) 27(67.5%)
* STEMI; ST elevation myocardial infarction.
** P value < 0.05 is significant.below the age of 60 years; however above the age of 75 years,
women have a higher incidence [31]. In this study; male preva-
lence was significantly higher between the STEMI and the stable
angina patients but less among the control.
In this study, regarding conventional risk factors of CADs, dia-
betes mellitus, smoking and hypertension were associated with
increased risk of CADs. On the other hand, dyslipidemia and posi-
tive family history of CADs did not have a significant effect on haz-
ard rate among our patients.
The genotype and allele frequencies for the PAI-1 4G/5G poly-
morphism in the control group were (5G/5G) 21.6%, (4G/4G + 4G/
5G) 78.4%, (5G) 60.8% and (4G) 39.2% respectively. The genotypic
distribution of 4G/5G polymorphism differed significantly in sev-
eral studies by race. Panahloo et al., detected frequencies of 21%
for 5G/5G, 50% for 4G/5G and 29% for 4G/4G genotype among
white control participants and of 67%, 33% and 0% among Afri-
can–Americans respectively [32]. Festa et al. studied the same
polymorphism among 3 ethnic groups (non-Hispanic whites, His-
panics and black) and detected significant differences regarding
the genotypic distribution (p = 0.001) [33].
The present study did not detect a significant difference in the
genotype and allele frequencies of the PAI-1 4G/5G polymorphism
when CAD patients were compared to the control group (p 0.25, p
0.55 respectively). Association of the PAI-1 4G/5G promoter poly-
morphism and CAD is still a controversial issue with some studies
linking its association [27,34,35] while others not [19,36–42].
Senol et al., did not find any statistical significant differences when
preoperative coronary artery bypass grafting (CABG) patients with
STEMI were compared to a control group [43]. However, Gongps.






Association between PAI-1 4G/5G, and PAI C/G polymorphisms and different parameters and risk of CADs.
STEMI* & stable angina patients Control group P value Odds ratio (95% CI)
Gender
Men (N/%) 79(75%) 16(41%) <0.001** 4.37 (2.01–9.50)
Women (N/%) 26(25%) 23(59%)
Diabetic
Yes (N/%) 22(21%) 1 (2.6%) <0.001** 10.07 (1.31–77.50)
No (N/%) 83(79%) 38(97.4%)
Smokers
Yes (N/%) 44(42%) 6 (15.4%) 0.001** 3.97 (1.53–10.29)
No (N/%) 61(58%) 33(84.6%)
Hypertensive
Yes (N/%) 42(40%) 8 (20.5%) 0.024** 2.58 (1.08–6.18)
No (N/%) 63(60%) 31(79.5%)
Dyslipidemia
Present (N/%) 7(7%) 7 (17.7%) 0.054 0.32 (0.11–1.00)
Absent (N/%) 98(93%) 32(82.1%)
FH*** for CAD
Present (N/%) 26(25%) 6 (15.4%) 0.216 1.81 (0.68–4.80)
Absent (N/%) 79(75%) 33(84.6%)
PAI 4G/5G
Genotypes
5G/5G 33 (31.7%) 8 (21.6%) 0.25 0.59 (0.25–1.43)
4G/4G + 4G/5G 71 (68.3%) 29 (78.4%)
Allele frequency




CC 20 (27%) 12 (35.3%) 0.38 1.43 (0.62–3.51)
CG + GG 54 (73%) 22 (64.7%)
Allele frequency
C 54.1% 64.7% 0.14 1.56 (0.86–2.82)
G 45.9% 35.3%
* STEMI; ST elevation myocardial infarction.
** P value < 0.05 is significant.
*** Family history.
Table 5
Comparison of PAI-1 activity in STEMI, stable angina and control groups.
STEMI* N = 41 Stable angina N = 56 Control N = 31 P value**
PAI-1 activity ng/ml
Median (range)
2(0–13.6) 2(0–13.6) 2(0–12) 0.933
* STEMI; ST elevation myocardial infarction.
** P value < 0.05 is significant.
Table 6
Comparison of PAI-1 activity between mutant and non-mutant PAI-1 4G/5G and C/G
genotypes in STEMI patients.






Mutant (4G/4G + 5G/
4G)
Control group 1(1–6) 4.6 (0–11) 0.262
Stable angina 1.25(0–13.6) 2 (0–13.6) 0.373
STEMI* patients 1.8 (0–13) 2 (0–13.6) 0.379
PAI-1C/G polymorphism Wild (CC) Mutant (CG + GG)
Control group 3.3 (1–6) 4.6 (0–11) 0.495
Stable angina 3.3(0–13.6) 2(0–13) 0.756
STEMI patients 2.0(0–13.6) 2(0–13) 0.944
* STEMI; ST elevation myocardial infarction.
** P value < 0.05 is significant.
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et al. study, associated it to the decreased risk of MI in young
women [42].Our study assessed the active PAI-1 levels. The active PAI-1
levels in the 3 studied groups did not differ significantly (p =
0.933) and no significant differences were detected between wild
and mutant genotypes regarding the level of active PAI-1 levels
in the different studied groups. A former study investigated the
PAI-1 levels in different races: its level was the lowest in blacks fol-
lowed by non-Hispanic whites then Hispanics (p 0.0001) [33].
It has been postulated that PAI-1 4G/5G polymorphism is asso-
ciated with different levels of PAI -1 protein as the presence of
4G/4G genotype is associated with increased levels of PAI-1 in
plasma and increased myocardial infarction risk [27,34,35].
Isordia-Salas et al. [45] and Eriksson et al. [27] detected a higher
plasma level in patients who were homozygous for the 4G allele.
Similarly, Festa et al., detected the highest PAI-1 plasma level in
subjects with a 4G/4G genotype, intermediate level for those with
a 5G/4G genotype and the lowest for the 4G/4G genotype [33].
Among our studied groups the genotype 4G/4G was detected
only in 2 cases of the stable angina patients and was not detected
in any of the control or STEMI patients and this hampered reaching
330 H. Al-Wakeel et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 325–331a conclusion on the association between 4G allele and active PAI-1
levels. Extended studies are needed to elucidate the effect of 4G/4G
genotype on PAI-1 activity and levels among the Egyptian
population.
The genotype distribution and allele frequencies for the PAI-1C/
G polymorphism in the control group were: (C/C) 35.3%, (C/G)
62.7% (G/G) 2%, (C) 64.7% and (G) 35.3% respectively. Among nor-
mal subjects, Barlik et al., detected frequencies of (C/C) 35.6%, (C/
G) 44.4%, (GG) 20%, (C) 57.8% and (G) 42.2% [46], while Torres-
Carillio et al. in 132 Mexicans, detected frequencies of 49.2%,
44.7% and 6.1% [24] in genotypes respectively.
To the best of our knowledge, the PAI-1C/G polymorphism has
not been extensively investigated in CAD patients. The present
study did not detect a significant difference in the distribution of
genotypes and allele frequencies of the PAI-1C/G polymorphism
when CAD patients were compared to the control group (p 0.38,
p 0.14 respectively).
On studying the effect of the presence of combined mutant
genotypes or alleles in CAD patients, STEMI patients showed signif-
icantly higher frequencies for the presence of combined mutant
alleles of PAI-1 4G/5G and PAI-1C/G polymorphisms (p 0.016) rais-
ing the possibility of multifactorial genetic alteration predisposi-
tion to acute coronary syndrome.
In conclusion, no significant association between PAI-1 4G/5G
and C > G polymorphisms and the risk of coronary artery disease
or the activity level of PAI-1 were detected among the studied pop-
ulation. However, STEMI patients showed presence of combined
mutant allele of both genes more frequently. Further multicenter
studies on a larger sample are recommended to study the effect
of combined PAI-1 genetic alteration on the risk of coronary artery
disease.
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